Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1471

Sort by

Sort Order Select

Journal Articles

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure

Blood (2019) 134 (Supplement_1): 1554.

https://doi.org/10.1182/blood-2019-129199

Published: 2019

Journal Articles

The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival

Lourdes Calvente, MD, Manjula Maganti, MSc, Mary Gospodarowicz, MD FRCPC, David C. Hodgson, MD MPH, FRCPC, Danielle Rodin, MD MPH, FRCPC, Alexander Sun, MD FRCPC, Richard Tsang, MD FRCPC, Robert Kridel, MDMPH,PhD, Vishal Kukreti, MD, Anca Prica, MD, Michael Crump, MD FRCPC, John Kuruvilla, MD

Blood (2019) 134 (Supplement_1): 1559.

https://doi.org/10.1182/blood-2019-130282

Published: 2019

Journal Articles

Genetic Characteristics and Clinical Outcomes of T-Cell Acute Lymphoblastic Leukemia; Myeloid-Suppressive Therapeutic Approach Based on Allogeneic Hematopoietic Cell Transplantation May Benefit in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Jae-Ho Yoon, MD PhD, Han Bi Lee, Gi June Min, MD, Sung-Soo Park, Silvia Park, Byung Sik Cho, MD PhD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Hee-Je Kim, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Jong Wook Lee, MD PhD, Seok Lee, MD PhD

Blood (2019) 134 (Supplement_1): 1470.

https://doi.org/10.1182/blood-2019-129870

Published: 2019

Journal Articles

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Wellington F Silva, MD, Lidiane Inês Da Rosa, MD, Fernanda S Seguro, MD, Douglas R. A. Silveira, Luciana Nardinelli, M.Sc, Valeria Buccheri, MD PhD, Elvira DRP Velloso, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1354.

https://doi.org/10.1182/blood-2019-127202

Published: 2019

Journal Articles

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Timothy S. Pardee, MD PhD, Kris C Wood, PhD, Kevin H Lin, BS, Justine Rutter, PhD, Mariaelena Pierobon, MD, Emanuel Petricoin, PhD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 1388.

https://doi.org/10.1182/blood-2019-129413

Published: 2019

Journal Articles

Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex

Hui-qiang Huang, Gao Yan, Hang Su, Yunhong Huang, Yuhuan Gao, Wang Xiaoxiao, Bai Bing, Yujing Zhang, Liping Su, Xiaoxia Chu, Wenyu Li, MD PhD, Junyi Zhang, Qiaohua Zhang, MD, Liansheng Zhang, Xiaohua Hu, Liqun Zou, Zhiming Li, Wenqi Jiang

Blood (2019) 134 (Supplement_1): 1569.

https://doi.org/10.1182/blood-2019-123478

Published: 2019

Journal Articles

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Xiaoxian Zhao, PhD, Bartlomiej Przychodzen, Juraj Bodo, PhD, Lisa Durkin, Daniel Lindner, MD PhD, Neetha Parameswaran, PhD, Michael Clemente, MS, Sarah L. Ondrejka, DO, Jaroslaw P. Maciejewski, MD PhD, Deepa Jagadeesh, MDMPH, Eric D. Hsi, MD

Blood (2019) 134 (Supplement_1): 1572.

https://doi.org/10.1182/blood-2019-129131

Published: 2019

Journal Articles

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Craig W. Freyer, PharmD, Wenyan Ji, MA, Tara L. Cronin, BA, Swapna Thota, MD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Jeffrey Baron, PharmD, Mark Walsh, PharmD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 1361.

https://doi.org/10.1182/blood-2019-130582

Published: 2019

Journal Articles

Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy

Sangmin Lee, MD, Ellen K. Ritchie, MD, Sumaiya Miah, Caroline Andy, Tania Curcio, Finola Goudy, Michael Hovan, Claire Douglass, Pinkal Desai, MDMPH, Michael B. Samuel, MD, Gail J. Roboz, MD, Michael Satlin, MD, M.S.

Blood (2019) 134 (Supplement_1): 1336.

https://doi.org/10.1182/blood-2019-125441

Published: 2019

Journal Articles

Prospective Identification of Acute Myeloid Leukemia Patients Who Benefit from Gene-Expression Based Risk Stratification

Diego Chacon, PhD, Ali Braytee, PhD, Yizhou Huang, PhD, Julie Thoms, PhD, Shruthi Subramanian, BSc, Maria Cristina Sauerland, Stefan K. Bohlander, MD, Jan Braess, MD, Bernhard J. Wörmann, MD, Wolfgang E. Berdel, MD, Wolfgang Hiddemann, MD PhD, Bogdan Gabrys, PhD, Klaus H. Metzeler, MD, Tobias Herold, MD, John Pimanda, MBBS, PhD, Dominik Beck, PhD

Blood (2019) 134 (Supplement_1): 1397.

https://doi.org/10.1182/blood-2019-129519

Published: 2019

Journal Articles

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Sunnia T Chen, BS, Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Cristine Allmer, BS, Dennis P. Robinson, Grzegorz Nowakowski, MD, Thomas M. Habermann, MD, Susan L Slager, PhD, Carrie A. Thompson, MD, James R. Cerhan, MD PhD

Blood (2019) 134 (Supplement_1): 5215.

https://doi.org/10.1182/blood-2019-128775

Published: 2019

Journal Articles

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Antonis Patrinos, MD, Maria Melachrinou, MD PhD, Alexandra Kourakli, MD PhD, Vassiliki Pappa, MD, Maria K. Angelopoulou, MD, Anastasia Sioni, Nikolaos Kanellias, MD, Sofia Chatzileontiadou, MD, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, MD PhD, Maria Papaioannou, Evangelos Terpos, MD PhD, Gerasimos Pangalis, MD, Theodoros P. Vassilakopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5340.

https://doi.org/10.1182/blood-2019-130219

Published: 2019

Journal Articles

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 5311.

https://doi.org/10.1182/blood-2019-129362

Published: 2019

Journal Articles

Extranodal NK/T Cell Lymphoma Nasal Type: A Cohort Study from Latin America

Lidiane Inês Da Rosa, MD, Wellington Fernandes da Silva, MD, Andre Abdo, MD, Eduardo M Rego, MD PhD, Vanderson Rocha, MD PhD, Juliana Pereira, MD PhD

Blood (2019) 134 (Supplement_1): 5284.

https://doi.org/10.1182/blood-2019-126307

Published: 2019

Journal Articles

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Melissa C Larson, MS, Cristine Allmer, BS, Susan L. Slager, PhD, Thomas M. Habermann, MD, Sunnia T Chen, BS, Hector R Villarraga, MD, Joerg Herrmann, MD, Gita Thanarajasingam, MD, Alessia Castellino, MD, Grzegorz Nowakowski, MD, David J Inwards, MD, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2019) 134 (Supplement_1): 422.

https://doi.org/10.1182/blood-2019-127203

Published: 2019

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 834.

https://doi.org/10.1182/blood-2019-129042

Published: 2019

Journal Articles

An Assessment of Race As a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B Cell Lymphoma

Ahmed Toure, BA, Yiyuan Wu, MS, Paul J Christos, Dr.P.H., M.S., Peter Martin, FRCPC, MD MS

Blood (2019) 134 (Supplement_1): 2205.

https://doi.org/10.1182/blood-2019-131567

Published: 2019

Journal Articles

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Bernice Oh, MBBS, MRCP, Shawn Lee, MD, Zelia Seeto, Germaine Liew, Bsc, Edwynn Chiew, MBBS, Zhi Wei Chen, Bsc, Yiong Huak Chan, PhD, Jing Jia Eng, Bsc, Koon Mian Foo, Bsc, Ching Mei Joyce Lam, MD, Ah Moy Tan, MD, Allen Eng Juh Yeoh, MD

Blood (2019) 134 (Supplement_1): 1307.

https://doi.org/10.1182/blood-2019-122098

Published: 2019

Journal Articles

Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study

Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Xiaoyi Wang, MD MPH, Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Scott F. Huntington, MD MPH, Natalia Neparidze, MD, Smith Giri, MBBS, MHS, Steven D. Gore, MD, Xiaomei Ma, PhD, Amy J Davidoff, PhD MS, Rong Wang, PhD

Blood (2019) 134 (Supplement_1): 116.

https://doi.org/10.1182/blood-2019-126643

Published: 2019

Journal Articles

Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Children's Oncology Group

Kelly D Getz, Lillian Sung, MD PhD, Robert B. Gerbing, Todd A. Alonzo, PhD, Yimei Li, PhD, Yuan-Shung V. Huang, MS, Kasey J Leger, MD MSc, Jessica A. Pollard, MD, Todd M Cooper, DO, Edward Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 331.

https://doi.org/10.1182/blood-2019-131227

Published: 2019

NARROW

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure

The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival

Genetic Characteristics and Clinical Outcomes of T-Cell Acute Lymphoblastic Leukemia; Myeloid-Suppressive Therapeutic Approach Based on Allogeneic Hematopoietic Cell Transplantation May Benefit in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy

Prospective Identification of Acute Myeloid Leukemia Patients Who Benefit from Gene-Expression Based Risk Stratification

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Extranodal NK/T Cell Lymphoma Nasal Type: A Cohort Study from Latin America

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

An Assessment of Race As a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B Cell Lymphoma

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study

Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Children's Oncology Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only